Cargando…

Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays

BACKGROUND: Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa‐like procoagulant activity in units relevant to their respec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yideng, Jackson, Joseph W., Woodle, Samuel A., Surov, Stepan S., Parunov, Leonid A., Scott, Dorothy E., Weinstein, Mark, Lee, Timothy K., Ovanesov, Mikhail V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles ‐ Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845073/ https://www.ncbi.nlm.nih.gov/pubmed/33537546 http://dx.doi.org/10.1002/rth2.12467

Ejemplares similares

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor
por: Liang, Yideng, et al.
Publicado: (2023)

Effect of pH on thrombin activity measured by calibrated automated thrombinography
por: Jackson, Joseph W., et al.
Publicado: (2020)

Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice
por: Xu, Yanqun, et al.
Publicado: (2020)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing
por: Gosselin, Robert C., et al.
Publicado: (2021)

Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
por: Jordan Bruno, Ximena, et al.
Publicado: (2022)

Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples
por: Chang, William C., et al.
Publicado: (2021)

Traumatic vessel injuries initiating hemostasis generate high shear conditions
por: Yakusheva, Alexandra A., et al.
Publicado: (2022)

Structural, functional, and immunogenicity implications of F9 gene recoding
por: Katneni, Upendra K., et al.
Publicado: (2022)

Correction of microplate location effects improves performance of the thrombin generation test
por: Liang, Yideng, et al.
Publicado: (2013)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
por: Thomas, Dirk, et al.
Publicado: (2019)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study
por: Murray, Suzanne, et al.
Publicado: (2019)

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance
por: Keller, Karsten, et al.
Publicado: (2019)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
por: Li, Chan, et al.
Publicado: (2019)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

The intestinal microbiome potentially affects thrombin generation in human subjects
por: Mohammed, Yassene, et al.
Publicado: (2019)

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex
por: Gierula, Magdalena, et al.
Publicado: (2019)

Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h4cupe74fppliq8nvt59tijg0b